Synchron's 180-Day Safety Test Cannot Prove Its Wireless Implant Works
Synchron has paused enrollment over a lead performance issue. The harder problem is proving that the redesigned wireless system can deliver reliable signals before enrollment resumes.
The wireless Stentrode still has a cable. Of course it does. The external wire is gone, but an internal lead still carries signals to implanted electronics. In a statement quoted by WIRED on 12 November 2026, Synchron said a performance issue involving that lead prompted its voluntary pause in enrollment for second-generation trials. It said the issue did not involve the Stentrode itself and that no related safety problems had been identified. Participants already implanted keep their devices.
We think investors are watching the wrong clock. We call it the reliability checkpoint: completed upgrades, resumed enrollment and disclosed functional readouts from the upgraded hardware, with a participant count and duration, that turn a repair into evidence that the system works; Synchron's stated condition for resuming recruitment is completion of the hardware upgrades. Our test asks more. If you value the successor today, you are paying for an observation that has yet to be published.
Look at what the trials count. INTENT in the US tracks device-related serious adverse events for 180 days after implantation. FOCUS in Australia counts serious events causing death or permanently increased disability through 90 days. Australia also lists stability of recorded BCI signals up to one year as another outcome: the program is looking for sustained functional performance, yet its primary endpoint can be met through safety observations alone, leaving you to judge the interface's stability from a separate result. If you confuse the two, you mistake a clinical measurement for a commercial achievement.
The INTENT registry, updated 5 November 2026, lists 10 estimated participants and ACTIVE_NOT_RECRUITING. Australia's FOCUS entry, updated 6 November, lists another 10 estimated participants with the same status. Canada's FOCUS entry, also updated 6 November, lists one actual participant and termination for "Insufficient recruitment." Add them and you get 21 registry-listed enrollment places, mixing two estimates with one actual count, not 21 working second-generation implants. Canada's entry names no hardware cause. WIRED quotes the company statement explaining the wider enrollment pause.
The earlier Stentrode used an external wire and a chest-worn paddle. In March 2026, Tom Oxley described the wearable's delicate communication layer as a problem. The successor removes the external wire, uses fewer electrodes and connects over Bluetooth; the internal lead still carries signals. Synchron says it is bringing lead design and manufacturing in-house and upgrading the whole system. If you alter the signal path, you need observations on the altered path. What you learned about the old design stays useful. It does not do the new device's job for it.
Start with the money, because your cap table cannot wait for clinical evidence. Synchron announced a $200 million Series D on 6 November 2025, led by Double Point Ventures, and said cumulative funding reached $345 million. Forge Global lists the round at an $821.5 million post-money valuation. The round's size equals a 24.35% common-equivalent slice of that valuation, assuming equal economics. In a hypothetical 25% valuation markdown, company value falls by about $205.4 million and the equivalent Series D slice by $50 million, before preferences or dilution.
Australia's National Reconstruction Fund Corporation announced an A$54 million equity stake on 7 November 2025; an equivalent markdown on that investment is A$13.5 million. These are scenarios, not reported losses. Neither those numbers nor WIRED and the registries establish Synchron's runway, burn rate, lead repair cost, affected second-generation implant count or duration of usable upgraded signals.
These figures price an equity scenario. They cannot price the repair. Synchron's financing announcement earmarked proceeds for commercializing the first-generation Stentrode platform, developing "a frontier next-generation interface" and expanding its San Diego hub. WIRED says the early trials precede a larger pivotal trial needed for US marketing approval. You still have to fix the signal chain, enroll people, measure performance and make the pivotal case. Funding cannot do the measuring for you.
The strongest case for Synchron is that an early voluntary pause protects the evidence of a platform already working in people's lives. Oxley told WIRED that he retained "strong confidence" in its potential as a "first-line therapy"; this is the company's own view. Synchron said all six first-generation COMMAND participants met the primary safety endpoint at one year, with a median deployment time of 20 minutes.
More persuasive than the CEO's statement, Mitchell and colleagues found stable signal bandwidth in all four implanted SWITCH patients through 12 months, with mean selection accuracy of 93.9% and a mean typing rate of 16.6 correct characters per minute. Independent authors Pearl Saldanha, Melvin Vaupel, Benjamin Dunn and Jonathan Whitlock wrote in the European Physical Journal Special Topics on 1 April 2026 that Synchron "has effectively succeeded at the basic level of getting a BMI into real homes under real-world conditions." Their paper predates the pause. You have a respectable argument for fixing the component without abandoning the first-generation commercial path.
We take that argument seriously. It does not clear the successor's checkpoint. COMMAND measured first-generation safety; SWITCH's four patients showed stable signal bandwidth on the first-generation system. The authors assessed earlier achievements, before the wireless lead issue became public. If you buy the promise of the upgraded device, you need signals from that device. The prior results justify persistence. They do not deliver upgraded performance data.
Neuralink supplies the best example of the opposite outcome. In its 8 May 2024 update, the company said threads retracted in its first participant, reducing effective electrodes and cursor performance, before software changes restored performance. It gave a first-session cursor score of 4.6 bits per second and a later, undated score of 8.0, plus 69 hours of device use in a single week. Its 21 August update said it saw no thread retraction in a second participant after surgical changes and that he began controlling a cursor in under five minutes.
You can see a failure mechanism, a repair and a next-participant result. You can also count the sample: two people, company-sourced, using intracortical threads, with a software fix for the first participant, rather than Synchron's endovascular lead. That example shows what such a disclosure looks like. It cannot pass the checkpoint for Synchron.
Medtronic shows what a lead disclosure can contain. In October 2007, it voluntarily suspended distribution of Sprint Fidelis defibrillator leads and disclosed approximately 268,000 implanted as of 4 October, 665 confirmed fractures in returned leads and five deaths where a fracture may have contributed. An FDA record lists 235,000 units distributed for one model, a different measure. This was a marketed product subject to a Class 1 recall; Synchron reports no related safety issue and is pausing early trial enrollment. You cannot transfer Medtronic's failure experience to Synchron. You can ask for the same elementary disclosure: mechanism, affected count, next result.
We expect evidence to lag the engineering announcement. Our call, with moderate confidence, is that Synchron will reach the end of January 2027, INTENT's estimated primary-completion month, without clearing the wireless successor's reliability checkpoint. A Synchron statement published no later than the end of January 2027 reporting completed upgrades, resumed enrollment and functional signals from the upgraded system, with the participant count and duration of stable performance, would prove us wrong. If you own the risk, demand that document rather than celebrating a safety milestone.
How the numbers were built
The registry-listed enrollment sum is 10 estimated INTENT participants plus 10 estimated FOCUS Australia participants plus one actual FOCUS Canada participant, or 21 mixed registry enrollment places, not confirmed implants. The Series D common-equivalent share is $200 million divided by Forge's $821.5 million post-money valuation, or 24.35%, assuming equal economics and ignoring preferences and later dilution. In the hypothetical 25% markdown, $821.5 million multiplied by 25% gives $205.375 million, rounded to $205.4 million, and $200 million multiplied by 25% gives a $50 million change for the equivalent Series D slice. The Australian investment sensitivity is A$54 million multiplied by 25%, or A$13.5 million. None of the markdown figures represents a reported loss.